Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod

BACKGROUND: The assessment of the safety and the humoral response to a third booster dose of the BNT162b2 mRNA COVID-19 vaccine is relevant in patients with Multiple Sclerosis (pwMS) treated with Ocrelizumab (OCR) or Fingolimod (FNG). METHODS: Serum samples were collected from Healthy controls (HCs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Capuano, Rocco, Altieri, Manuela, Conte, Miriana, Bisecco, Alvino, d’Ambrosio, Alessandro, Donnarumma, Giovanna, Grimaldi, Elena, Coppola, Nicola, Medici, Nicola, Galdiero, Massimiliano, Tedeschi, Gioacchino, Gallo, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314242/
https://www.ncbi.nlm.nih.gov/pubmed/35879563
http://dx.doi.org/10.1007/s00415-022-11296-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314242/
https://www.ncbi.nlm.nih.gov/pubmed/35879563
http://dx.doi.org/10.1007/s00415-022-11296-4

Ejemplares similares